Search

AstraZeneca PLC

Abrir

SetorSaúde

11,678 2.6

Visão Geral

Variação de preço das ações

24h

Atual

Mín

11382

Máximo

11794

Indicadores-chave

By Trading Economics

Rendimento

-1.4B

2.5B

Vendas

-94M

15B

P/E

Médio do Setor

25.587

64.641

EPS

2.63

Margem de lucro

16.296

Funcionários

96,100

EBITDA

-694M

5B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+39.94% upside

Dividendos

By Acuity

Próximos Ganhos

30 de out. de 2026

Próxima data de dividendos

8 de set. de 2026

Próxima data de ex-dividendo

6 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

558M

263B

Abertura anterior

11675.4

Fecho anterior

11678

Sentimento de Notícias

By Acuity

42%

58%

133 / 340 Ranking em Healthcare

AstraZeneca PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 23:56 UTC

News

Diversified Healthcare Trust reported second-quarter FFO of $0.16, exceeding estimates. Revenue fell short at $365.39 million, contributing to a decline in after-market trading.

3 de ago. de 2026, 23:56 UTC

News

First Solar Inc reported second-quarter revenue of $1.06 billion and a net profit of $423 million. Shares are higher in after-hours trading.

3 de ago. de 2026, 23:52 UTC

Social Media
Correlated Moves
News

Microsoft shares are lower in after-market hours amid a class action lawsuit alleging misrepresentation of its Copilot products' performance and competitive position.

3 de ago. de 2026, 23:51 UTC

News

Marvell Technology plans a conference call for August 27, 2026, and an Investor Day on October 6, 2026. Shares are higher in after-market trading.

3 de ago. de 2026, 23:51 UTC

News

Rivian Automotive raises 2026 capital expenditure guidance to $1.7B-$1.8B, shares trade higher in after-market hours amid focus on cost management and production scaling.

3 de ago. de 2026, 23:51 UTC

News

JELD-WEN Holding Inc. reported second-quarter revenue of $817.8 million, exceeding forecasts. The company raised its full-year revenue guidance, boosting after-market trading sentiment.

3 de ago. de 2026, 23:51 UTC

Social Media
News

Palantir Technologies reported Q2 revenue of $1.94 billion, exceeding expectations. Shares rose sharply in after-market hours following strong earnings and raised guidance.

3 de ago. de 2026, 23:51 UTC

Social Media
News

Snap Inc. reported a narrower net loss of $163.96 million and revenue of $1.60 billion, exceeding expectations. Shares rose during after-market trading.

3 de ago. de 2026, 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

3 de ago. de 2026, 23:46 UTC

News

CVS Health shares rose in after-market hours following a survey showing increased provider-payer trust scores and improved perceptions of digital tools in healthcare.

3 de ago. de 2026, 23:46 UTC

News

Alexandria Real Estate Equities reported a narrower net loss and FFO of $1.73, exceeding estimates. Shares traded higher in after-market hours.

3 de ago. de 2026, 23:46 UTC

Correlated Moves
News

Nova Ltd's after-market shares are higher, bolstered by strong analyst sentiment and a consensus price target of $603.38, reflecting a potential 54.4% return.

3 de ago. de 2026, 23:46 UTC

News

Realty Income Corp reported first-quarter revenue of nearly $1.55 billion, with adjusted funds from operations increasing to $1.06 billion. Shares were roughly flat after-market.

3 de ago. de 2026, 23:41 UTC

News

Teladoc Health remains effectively unchanged in after-market trading. Citigroup lowered its price target from $11.00 to $7.50 while maintaining a "neutral" rating.

3 de ago. de 2026, 23:41 UTC

News

Addus Homecare Corp reported Q2 revenue of $377.4 million and adjusted EPS of $1.73. Shares declined after the earnings announcement amid mixed market reactions.

3 de ago. de 2026, 23:41 UTC

News

Hims & Hers Health shares are higher in after-market trading, following positive growth insights despite facing a lawsuit from the Federal Trade Commission.

3 de ago. de 2026, 23:41 UTC

Correlated Moves
News

DA Davidson raised its price target for First Business Financial Services to $80, contributing to higher shares in after-market trading.

3 de ago. de 2026, 23:41 UTC

News

Karyopharm Therapeutics shares are lower in after-market hours following the grant of restricted stock units to a new employee, raising potential dilution concerns.

3 de ago. de 2026, 23:41 UTC

News

Andersons Inc. shares rise in after-market trading following strong Q2 results, with adjusted net income of $73.6 million exceeding expectations.

3 de ago. de 2026, 23:41 UTC

Social Media
News

BWX Technologies shares are lower in after-market hours following a revenue miss of $901.6 million and a divestiture of its medical business to Nordic Capital.

3 de ago. de 2026, 23:41 UTC

Social Media
News

Williams Companies announced an agreement to acquire Momentum Midstream for up to $5.5 billion, boosting its natural gas infrastructure and supporting Gulf Coast demand.

3 de ago. de 2026, 23:41 UTC

News

Ichor Holdings shares lower in after-market trading following a revenue miss of $294.8 million and EPS of $0.03, below expectations.

3 de ago. de 2026, 23:31 UTC

News

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

3 de ago. de 2026, 23:31 UTC

News

Ameresco shares rose in after-market trading following strong Q2 results, with revenues of $515.5 million exceeding expectations and a record $1.8 billion in new project awards.

3 de ago. de 2026, 23:31 UTC

News

UBS raised its price target on Colgate-Palmolive Co to $109, maintaining a Buy rating. Shares are trading higher in after-market hours.

3 de ago. de 2026, 23:31 UTC

Social Media
News

Grab Holdings reported strong Q2 results, with earnings per share of 6 cents and revenue of $997 million. Shares are higher in after-market hours.

3 de ago. de 2026, 23:31 UTC

News

Ultra Clean Holdings reported Q2 net income of $11.9 million and revenue of $644.9 million, raising its Q3 outlook to between $700 million and $750 million.

3 de ago. de 2026, 23:26 UTC

Social Media
News

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, exceeding estimates. The company raised its full-year guidance to between $13.1 billion and $13.2 billion.

3 de ago. de 2026, 23:21 UTC

News

Banner Corp announces a buyback of up to 1.7 million shares, aiming to enhance long-term shareholder value. Shares are higher in after-market trading.

3 de ago. de 2026, 23:21 UTC

News

Inspire Medical Systems reported Q2 adjusted EPS of $0.14, exceeding expectations. The company raised its full-year EPS guidance to between $1.05 and $1.45.

AstraZeneca PLC Previsão

Preço-alvo

By TipRanks

39.94% parte superior

Previsão para 12 meses

Média 16,093.33 GBX  39.94%

Máximo 20,200 GBX

Mínimo 11,500 GBX

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para AstraZeneca PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

12

Comprar

1

Manter

1

Vender

Sentimento

By Acuity

133 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Acima da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
help-icon Live chat